Full Press Release Details
ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON JANUARY 19, 2022
To the shareholders of XTL Biopharmaceuticals
Notice is hereby given that an Annual General
Meeting (the "Annual Meeting") of the shareholders of XTL Biopharmaceuticals Ltd. (the "Company") will
be held at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 Metsada St., B.S.R Tower
4, Bnei Brak, Israel at 15:00 PM (Israel Time), on January 19, 2022.
The agenda of the Annual Meeting will be as follows:
| 1. | To discuss the auditor's report of our independent registered public accounting firm and audited financial statements for the year ended as of December 31, 2020. | |
| 2. | To appoint Somekh Chaikin, Certified Public Accountants in Israel and a member firm of KPMG as the Company's independent auditors for the fiscal year ending December 31, 2021, instead of Kesselman & Kesselman, Certified Public Accountants, a member firm of PrincewaterhouseCoopers International Limited, and to authorize the Board of Directors, upon the recommendation of the Company's audit committee (the " Audit Committee "), to determine the auditors' remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year. | |
| 3. | To re-elect Messrs. Alexander Rabinovitch, Dr. Jonathan Schapiro, Shlomo Shalev, Doron Turgeman and Dr. Dobroslav Melamed to our Board of Directors, each for a term expiring at our next annual general meeting of shareholders (a separate vote for each director will be taken). Declaration of Directors Qualification is attached as Annex A hereto. |
Only shareholders and holders of ordinary shares
represented by American Depositary Shares at the close of business on December 19, 2021 (the "Record Date") are entitled
to notice of, and to vote at, the Annual Meeting and any adjournment or postponement thereof. You are cordially invited to attend the
Annual Meeting in person.
If you are unable to attend the Meeting in person,
you are requested to complete, date and sign the enclosed proxy and to return it promptly in the pre-addressed envelope provided. Shareholders
who attend the Annual Meeting may revoke their proxies and vote their shares in person.
Beneficial owners who hold ordinary shares through
members of the Tel Aviv Stock Exchange, or the TASE, may either vote their shares in person at the Annual Meeting by presenting a certificate
signed by the TASE Clearing House member through which the shares are held, which complies with the Israel Companies Regulations (Proof
of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares on the record date, or send such certificate along
with a duly executed proxy (in the form filed by us on MAGNA, the distribution site of the Israeli Securities Authority, at www.magna.isa.gov.il),
to us at 5 Badner Street, Ramat Gan 5218102, Israel, Attention: Chief Executive Officer.
| By Order of the Board of Directors | |
| /s/ Shlomo Shalev | |
| Shlomo Shalev Chief Executive Officer Dated: _____________ |
Ramat Gan, Israel, 5218102
FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON JANUARY 19, 2022
This Proxy Statement is furnished
to our holders of ordinary shares, par value NIS 0.1 per share and holders of our ordinary shares that are represented by American Depository
Shares, or ADSs, in connection with Annual general meeting of shareholders (the "Annual Meeting"), to be held on January 19, 2022,
at 15:00 PM Israel time at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross, at 7 Metsada St.,
B.S.R Tower 4, Bnei Brak, Israel.
Throughout this Proxy Statement,
we use terms such as "XTL Biopharmaceuticals," "XTL," "we", "us", "our" and
the "Company" to refer XTL Biopharmaceuticals Ltd. and terms such as "you" and "your" to refer to
our shareholders and ADS holders.
The agenda of the Annual
Meeting will be as follows:
1. To discuss the auditor's
report of our independent registered public accounting firm and audited financial statements for the year ended December 31, 2020.
2. To appoint Somekh Chaikin,
Certified Public Accountants in Israel and a member firm of KPMG as the Company's independent auditors for the fiscal year ending
December 31, 2021, instead of Kesselman & Kesselman, Certified Public Accountants, a member firm of PrincewaterhouseCoopers International
Limited., and to authorize the Boad of Directors, upon the recommendation of the Audit Committee to determine the auditors' remuneration
to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.
3. To re-elect Mr. Alexander
Rabinovitch to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
4. To re-elect Dr. Jonathan
Schapiro to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
5. To re-elect Mr. Shlomo
Shalev to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
6. To re-elect Mr. Doron
Turgeman to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
7. To re-elect Dr. Dobroslav
Melamed to our Board of Directors for a term expiring at our next annual general meeting of shareholders.
We currently are unaware
of any other matters that may be raised at the Annual Meeting. Should any other matters be properly raised at the Annual Meeting, the
persons designated as proxies shall vote according to their own judgment on those matters.
Board Recommendation
Our Board of Directors unanimously
recommends that you vote "FOR" each of proposals 2 to 7.
Only shareholders and ADS
holders at the close of business on December 19, 2021 shall be entitled to receive notice of and to vote at the
You can vote your ordinary
shares by attending the Annual Meeting. If you do not plan to attend the Annual Meeting, the method of voting will differ for shares
held as a record holder, shares held in "street name" (through a Tel Aviv Stock Exchange, or TASE, member) and shares underlying
ADSs that you hold. Record holders of shares will receive proxy cards. Holders of shares in "street name" through a TASE
member will also vote via a proxy card, but through a different procedure (as described below). Holders of ADSs (whether registered in
their name or in "street name") will receive voting instruction cards in order to instruct their banks, brokers or other
nominees on how to vote.
Shareholders of Record
If you are a shareholder
of record, you can submit your vote by completing, signing and submitting a proxy card, which has been published at www.magna.isa.gov.il,
to the Company's office at 5 Badner Street, Ramat Gan 5218102, Israel.
Please follow the instructions
Shareholders Holding in
"Street Name" through the TASE
If you hold ordinary shares
in "street name," that is, through a bank, broker or other nominee that is admitted as a member of the TASE, your shares
will only be voted if you provide instructions to the bank, broker or other nominee as to how to vote, or if you attend the Annual Meeting
If voting by mail, you must
sign and date a proxy card in the form filed by us on MAGNA on December 16, 2021 and attach to it a certificate signed by the TASE Clearing House
member through which the shares are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General
Meetings)-2000 as proof of ownership of the shares on the record date, and return the proxy card, along with the proof of ownership certificate,
to the offices of our attorneys, Doron Tikotzky Kantor Gutman Nass & Amit Gross. (Attention: Ronen Kantor, Adv.) located at 7 Metsada
st., B.S.R Tower 4, Bnei Brak, Israel, as described in the instructions available on MAGNA.
If you choose to attend the
Annual Meeting (where ballots will be provided), you must bring the proof of ownership certificate from the TASE's Clearing House
member through which the shares are held, indicating that you were the beneficial owner of the shares on the record date.
Under the terms of the Deposit
Agreement between the Company, The Bank of New York Mellon, as depositary, or BNY Mellon, and the holders of our ADSs, BNY Mellon shall
endeavor (insofar as is practicable) to vote or cause to be voted the number of shares represented by ADSs in accordance with the instructions
provided by the holders of ADSs to BNY Mellon. For ADSs that are held in "street name", through a bank, broker or other nominee,
the voting process will be based on the underlying beneficial holder of the ADSs directing the bank, broker or other nominee to arrange
for BNY Mellon to vote the ordinary shares represented by the ADSs in accordance with the beneficial holder's voting instructions.
If no instructions are received by BNY Mellon from any holder of ADSs (whether held directly by a beneficial holder or in "street
name") with respect to any of the shares represented by the ADSs on or before the date established by BNY Mellon for such purpose,
BNY Mellon shall not vote or attempt to vote the shares represented by such ADSs.
Multiple Record Shareholders
You may receive more than
one set of voting materials, including multiple copies of this document and multiple proxy cards or voting instruction cards. For example,